Colson AE, Kumar PN, Ruane PJ, Chetchotisakd P, et al. Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial. Lancet 2026 Aug 12:S0140-6736(26)01442-X. doi: 10.1016/S0140-6736(26)01442.
PMID: 42586113